

# Muscular Dystrophy - Pipeline Review, H2 2020

<https://marketpublishers.com/r/M0633E79524EN.html>

Date: November 2020

Pages: 287

Price: US\$ 2,000.00 (Single User License)

ID: M0633E79524EN

## Abstracts

Muscular Dystrophy - Pipeline Review, H2 2020

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Muscular Dystrophy - Pipeline Review, H2 2020, provides an overview of the Muscular Dystrophy (Musculoskeletal Disorders) pipeline landscape.

Muscular dystrophy is a group of diseases in which muscle fibers are unusually susceptible to damage. These damaged muscles become progressively weaker. Symptoms usually appear before age 6 and may appear as early as infancy. They may include fatigue, learning difficulties, intellectual disability, muscle weakness and progressive difficulty walking.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Muscular Dystrophy - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Muscular Dystrophy (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Muscular Dystrophy (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Muscular Dystrophy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase

III, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 6, 41 and 21 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 1, 7 and 8 molecules, respectively.

Muscular Dystrophy (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Muscular Dystrophy (Musculoskeletal Disorders).

The pipeline guide reviews pipeline therapeutics for Muscular Dystrophy (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Muscular Dystrophy (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Muscular Dystrophy (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of

administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Muscular Dystrophy (Musculoskeletal Disorders)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Muscular Dystrophy (Musculoskeletal Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Muscular Dystrophy (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Muscular Dystrophy- Overview

Muscular Dystrophy- Therapeutics Development

Muscular Dystrophy- Therapeutics Assessment

Muscular Dystrophy- Companies Involved in Therapeutics Development

Muscular Dystrophy- Drug Profiles

Muscular Dystrophy- Dormant Projects

Muscular Dystrophy- Discontinued Products

Muscular Dystrophy- Product Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Muscular Dystrophy, H2 2020  
Number of Products under Development by Companies, H2 2020  
Number of Products under Development by Universities/Institutes, H2 2020  
Products under Development by Companies, H2 2020  
Products under Development by Universities/Institutes, H2 2020  
Number of Products by Stage and Target, H2 2020  
Number of Products by Stage and Mechanism of Action, H2 2020  
Number of Products by Stage and Route of Administration, H2 2020  
Number of Products by Stage and Molecule Type, H2 2020  
Muscular Dystrophy - Pipeline by Achelios Therapeutics Inc, H2 2020  
Muscular Dystrophy - Pipeline by AlloMek Therapeutics, H2 2020  
Muscular Dystrophy - Pipeline by Amicus Therapeutics Inc, H2 2020  
Muscular Dystrophy - Pipeline by AMO Pharma Ltd, H2 2020  
Muscular Dystrophy - Pipeline by Anima Biotech Inc, H2 2020  
Muscular Dystrophy - Pipeline by Armgo Pharma Inc, H2 2020  
Muscular Dystrophy - Pipeline by ARTHEx Biotech SL, H2 2020  
Muscular Dystrophy - Pipeline by Asklepios BioPharmaceutical Inc, H2 2020  
Muscular Dystrophy - Pipeline by Audentes Therapeutics Inc, H2 2020  
Muscular Dystrophy - Pipeline by Avidity Biosciences Inc, H2 2020  
Muscular Dystrophy - Pipeline by Benitec Biopharma Inc, H2 2020  
Muscular Dystrophy - Pipeline by Biophytis SA, H2 2020  
Muscular Dystrophy - Pipeline by Bioprojet SCR, H2 2020  
Muscular Dystrophy - Pipeline by CalyGene Biotechnology Inc, H2 2020  
Muscular Dystrophy - Pipeline by Casma Therapeutics Inc, H2 2020  
Muscular Dystrophy - Pipeline by Catabasis Pharmaceuticals Inc, H2 2020  
Muscular Dystrophy - Pipeline by Constant Therapeutics LLC, H2 2020  
Muscular Dystrophy - Pipeline by Corcept Therapeutics Inc, H2 2020  
Muscular Dystrophy - Pipeline by CRISPR Therapeutics AG, H2 2020  
Muscular Dystrophy - Pipeline by Design Therapeutics Inc, H2 2020  
Muscular Dystrophy - Pipeline by Dyne Therapeutics Inc, H2 2020  
Muscular Dystrophy - Pipeline by Edgewise Therapeutics, H2 2020  
Muscular Dystrophy - Pipeline by Elixirgen Therapeutics LLC, H2 2020  
Muscular Dystrophy - Pipeline by Enzerna Biosciences LLC, H2 2020  
Muscular Dystrophy - Pipeline by Exodos Life Sciences Limited Partnership, H2 2020  
Muscular Dystrophy - Pipeline by Expansion Therapeutics Inc, H2 2020

Muscular Dystrophy - Dormant Projects, H2 2020

Muscular Dystrophy - Discontinued Products, H2 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Muscular Dystrophy, H2 2020  
Number of Products under Development by Companies, H2 2020  
Number of Products under Development by Universities/Institutes, H2 2020  
Number of Products by Top 10 Targets, H2 2020  
Number of Products by Stage and Top 10 Targets, H2 2020  
Number of Products by Top 10 Mechanism of Actions, H2 2020  
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020  
Number of Products by Top 10 Routes of Administration, H2 2020  
Number of Products by Stage and Top 10 Routes of Administration, H2 2020  
Number of Products by Top 10 Molecule Types, H2 2020  
Number of Products by Stage and Top 10 Molecule Types, H2 2020

## I would like to order

Product name: Muscular Dystrophy - Pipeline Review, H2 2020

Product link: <https://marketpublishers.com/r/M0633E79524EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M0633E79524EN.html>